240 related articles for article (PubMed ID: 27276707)
1. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.
Broséus J; Chen G; Hergalant S; Ramstein G; Mounier N; Guéant JL; Feugier P; Gisselbrecht C; Thieblemont C; Houlgatte R
Oncotarget; 2016 Dec; 7(51):83987-84002. PubMed ID: 27276707
[TBL] [Abstract][Full Text] [Related]
2. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
3. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
4. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
6. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.
Guo L; Lin P; Xiong H; Tu S; Chen G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):85-96. PubMed ID: 29337112
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
9. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM; Joffe E; Batlevi CL; Hilden P; He J; Seshan VE; Zelenetz AD; Palomba ML; Moskowitz CH; Portlock C; Straus DJ; Noy A; Horwitz SM; Gerecitano JF; Moskowitz A; Hamlin P; Matasar MJ; Kumar A; van den Brink MR; Knapp KM; Pichardo JD; Nahas MK; Trabucco SE; Mughal T; Copeland AR; Papaemmanuil E; Moarii M; Levine RL; Dogan A; Miller VA; Younes A
Blood Cancer J; 2018 Jun; 8(6):60. PubMed ID: 29895903
[TBL] [Abstract][Full Text] [Related]
10. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
11. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
Modvig L; Vase M; d'Amore F
Br J Haematol; 2017 Oct; 179(1):75-82. PubMed ID: 28653321
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
[TBL] [Abstract][Full Text] [Related]
13. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
[TBL] [Abstract][Full Text] [Related]
16. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.
Kreisel F; Kulkarni S; Kerns RT; Hassan A; Deshmukh H; Nagarajan R; Frater JL; Cashen A
Cancer Genet; 2011 Mar; 204(3):129-37. PubMed ID: 21504712
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
18. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
19. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
[TBL] [Abstract][Full Text] [Related]
20. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
